The biotech stock rose nearly $7 a share from Monday through Thursday.
Compare VERV Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
Verve Therapeutics, Inc.
News & Analysis: Verve Therapeutics, Inc.
They only have preclinical candidates for now. But these biotechs could have game-changing gene-editing therapies.
Find out why these stocks are climbing higher.